Company Overview
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer. It also offers CHOICE, a technology and discovery and development platform; and developed an extensive library of isolated and engineered oncolytic VACV immunotherapeutic product candidates. The company has a licensing agreement with Newsoara BioPharma Co. Ltd. to research, develop, commercialize or exploit Olvi-Vec in China, including Mainland China, Taiwan, Hong Kong, and Macau, for human diagnostic, prophylactic, and therapeutic uses. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.15.
Recent Developments
- Dec 2025 Revenue of $8.00K (+0.0% YoY); net profit $-32.15M.
- Trailing 12 Months Year-on-year growth — revenue +0.0%.
- 5-Year Trend Long-term compounding — revenue CAGR -91.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -91.03% |
| 1 Year: | 0.00% |
Stock Price Performance
| 1 Year: | -20.63% |
| 6 Months: | -10.25% |
| 3 Months: | -13.31% |
| 1 Month: | -4.51% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)42.35 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Revenue declined at -91.0% CAGR over 5 years.
- Trading 69.2% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | GNLX Genelux Corporation PHARMA | 2.54 | -2.95 | $114.92M | 0.00% | - | - | -91.03% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 11.00M | 170.00K | - | - | 8.00K | - | - | - | - | - | - |
| Operating Income | -3.46M | -2.80M | 6.34M | -6.46M | -5.39M | -5.31M | -8.12M | -6.89M | -6.94M | -7.82M | -7.79M | -8.19M | -9.17M |
| Net Income | -3.80M | -2.82M | 4.91M | -10.36M | -5.82M | -5.34M | -7.85M | -6.58M | -6.47M | -7.49M | -7.46M | -7.95M | -8.93M |
| Diluted EPS | - | 0.31 | 0.49 | -0.53 | -0.23 | -0.20 | -0.29 | -0.22 | -0.19 | -0.21 | -0.20 | -0.21 | -0.20 |
| R&D Expense | 2.37M | 1.83M | 2.41M | 2.85M | 2.94M | 2.82M | 4.01M | 4.42M | 4.05M | 4.70M | 4.76M | 4.74M | 5.78M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 11.07M | 170.00K | 8.00K | 8.00K |
| Operating Income | -3.01M | -24.16M | -31.70M | -33.21M |
| Net Income | -5.21M | -28.30M | -29.87M | -32.15M |
| Diluted EPS | -0.57 | -1.16 | -0.95 | -0.86 |
| R&D Expense | 9.08M | 12.77M | 19.00M | 19.85M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 5.53M | 27.89M | 34.72M | 19.03M |
| Current Assets | - | 1.89M | 24.20M | 31.55M | 15.13M |
| Cash & Equivalents | - | 397.00K | 9.42M | 8.56M | 5.33M |
| Inventory | - | - | - | - | - |
| Receivables | - | - | - | - | - |
| Total Liabilities | - | 41.31M | 8.42M | 8.44M | 7.48M |
| Current Liabilities | - | 31.63M | 6.55M | 6.90M | 6.22M |
| Long Term Debt | 18.02M | 8.52M | - | - | - |
| Total Debt | - | 26.35M | 2.52M | 1.87M | 1.69M |
| Total Equity | - | -35.78M | 19.47M | 26.27M | 11.54M |
| Shares Outstanding | - | 23.57M | 27.22M | 35.16M | 38.57M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Operating Cash Flow | -3.57M | -20.27M | -21.23M | -25.27M |
| Investing Cash Flow | -49.00K | -14.72M | -8.13M | 12.14M |
| Financing Cash Flow | -478.00K | 44.02M | 28.51M | 9.89M |
| Capital Expenditure | -49.00K | -1.02M | -381.00K | -1.10M |
| Free Cash Flow | -3.62M | -21.30M | -21.61M | -26.37M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | - | - | - | - |
| Operating Margin % | -27.2% | -14,214.7% | -396,200.0% | -415,175.0% |
| Net Margin % | -47.0% | -16,645.3% | -373,362.5% | -401,812.5% |
| ROE % | 14.6% | -145.3% | -113.7% | -278.5% |
| ROCE % | 11.5% | -113.2% | -114.0% | -259.4% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Woodward Diversified Capital, LLC | 5.00% | 2.26M | $5.72M |
| 2 | Vanguard Capital Management LLC | 3.71% | 1.68M | $4.24M |
| 3 | Bleichroeder LP | 3.05% | 1.38M | $3.49M |
| 4 | Blackrock Inc. | 0.97% | 439.60K | $1.11M |
| 5 | Geode Capital Management, LLC | 0.97% | 439.21K | $1.11M |
| 6 | CM Management, LLC | 0.88% | 400.00K | $1.01M |
| 7 | Bank of America Corporation | 0.73% | 328.80K | $831.87K |
| 8 | Vanguard Fiduciary Trust Co | 0.52% | 236.34K | $597.95K |
| 9 | FLPutnam Investment Management Company | 0.51% | 231.41K | $585.45K |
| 10 | Global Retirement Partners, LLC | 0.50% | 227.85K | $576.47K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for GNLX
GNLX Forecast — Price Target — Prediction for 2027 - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE9kSUVnMTE1T2VweXBfUXFLQjBjaC1zR0NmLWtsUmlJTndNZmt5c2lDUWcxRHROOXZyTE1SZzdiSkJTUWtHdHE5ckxLQ3JaRWxCRVc5cDFwR2Q3SVNnZ2VLSGc1cG1EcUFnLTJvNUFyQW5RaXFNSDlSSnVR?oc=5" target="_blank">GNL…
Have Genelux Insiders Been Selling Stock? - simplywall.st
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxQS0ZLZGlGRXBhbFEwYTdGSVJSOWdTTzU5NU9TS0xJY2g3ZmVaU3ZGXzh2blFuOGZIZ1VjbVVjM1ZPMndiSEF0a1VEc0JHbzRETWM5eHhmYU95Nm5tTGhSeWM0eXVCeWt5UlhRS29PU3JFNTBUclFfYmFIaVgxUy1BV2F2b3ZnaTgzMGo4NW…
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxPbmdRTUNud1VsSExmdkhqUV9fZFcxem9Pd2FvM0FLMmI0cXI5NHFpNV9hODdJd1NiMDlBMU9IV1FfNHItcVRYN1RBZFJabHRBTHpwMkg2N0pHcjBmNnJUMEszaVRiUFA2d3ZFTGRxVDVJSEtCSlFmQXluR09kLVJNeGNudkNwQm5mQ21xb0…
$GNLX stock is down 10% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxQd3N3bGZvbmRwSzZTVnMyTVRtSkM0b2RKZGN6bDRiNEdURVp1OFlxUElQclo0TjZadklaNWVxNWxXV0F1QXdjYjRzcGRTbTNRZFUzUnhvZWhadjZrc0x0R1NJTkRfOFM1Yzg5bXZ4dkJJVWVuYW1YQWZkUndHZF95OWVOV0tUVzBWNVRfdl…
Genelux Corporation Common Stock (NASDAQ: GNLX) Stock Price, News & Analysis - kalkine.com.au
<a href="https://news.google.com/rss/articles/CBMiVkFVX3lxTE9zb2NPVDlNUFdQZFZQZDNkamc1SFVjal9ZMzJ0UFZ1THlDS3VBM1dDeWNpRzVwR2NsQjlyY2QwN0lqWXZwb2ZwSmpqeDhiU0FZck9mQUtn?oc=5" target="_blank">Genelux Corporation Common Stock (NASDAQ: GNLX) Sto…
Stay updated with the stocks that are on the move in today's after-hours session. - ChartMill
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxOVE1LTUZYX2ZXSnRyUklLZnFkckFvYXNNLXhMejdXYjM2bElLbGhkcDZHeUd1dldGZHptdnFtODFMOFloRmEwTGdlWFFLVHR1SkMzd2pJVlU4cUc5Sk9WTjlCdkJYQkJaeVcwa08tR0dwTFU0di1zRUFCenViTmxzb3NGcHJSQnJtNUIxTm…
GNLX — Frequently Asked Questions
What is the current share price of Genelux Corporation (GNLX)?
As of 2026-09-19 21:16 PDT, Genelux Corporation (GNLX) trades at $2.54 on NasdaqCM. Its 52-week range is $2.30 to $8.24.
What is the market capitalisation of GNLX?
Genelux Corporation (GNLX) has a market capitalisation of $114.92M on NasdaqCM.
What is the P/E ratio of GNLX?
GNLX trades at a trailing price-to-earnings (P/E) ratio of -2.95. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 7.01.
Is GNLX a good stock to buy?
This page provides a data-driven analysis of Genelux Corporation (GNLX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.